semaj83/ctmatch_classification huggingface dataset:
Patient description: A 52-year-old African American man with a history of heavy smoking and drinking, describes progressive dysphagia that began several months ago. He first noticed difficulty swallowing meat. His trouble swallowing then progressed to include other solid foods, soft foods, and then liquids. He is able to locate the point where food is obstructed at the lower end of his sternum. He has lost a total of 25 pounds.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Oropharyngeal Cancer Head and Neck Cancer Squamous Cell Carcinoma Patients with newly diagnosed, previously untreated squamous cell carcinoma of the head and neck (SCCHN) who are candidates for the molecular epidemiology study LAB00-062 of head and neck cancer Must have the ability to understand and provide informed consent Patients must be 18 years and older Ability to read, write, and speak English Resident of the United States Agrees to have tumor tissue, if available, tested for HPV. No additional biopsy will be requested  Previous cancer diagnosis excluding non-melanoma skin cancer Blood transfusion within the previous 6 months Immune suppression, such as HIV disease or immune-suppressing therapy (i.e., steroids)
Patient description: A 52-year-old African American man with a history of heavy smoking and drinking, describes progressive dysphagia that began several months ago. He first noticed difficulty swallowing meat. His trouble swallowing then progressed to include other solid foods, soft foods, and then liquids. He is able to locate the point where food is obstructed at the lower end of his sternum. He has lost a total of 25 pounds.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Esophageal Cancer Willing and able to provide informed consent Willing to comply with follow-up requirements Biopsy-confirmed esophageal cancer (adenocarcinoma or squamous cell carcinoma) in mid or distal esophagus (clinical stage 3 or less) Indicated for chemotherapy and/or radiation therapy Ability to dilate stricture to 15mm diameter at extent of disease evaluation Placement of at least 18 x 23mm diameter and 120mm length PolyFlex stent  Patients contraindicated for endoscopy Patients with prior esophageal stent placements Advance stage of disease, greater than T3 tumor or M1 disease
Patient description: A 52-year-old African American man with a history of heavy smoking and drinking, describes progressive dysphagia that began several months ago. He first noticed difficulty swallowing meat. His trouble swallowing then progressed to include other solid foods, soft foods, and then liquids. He is able to locate the point where food is obstructed at the lower end of his sternum. He has lost a total of 25 pounds.

Clinical trial eligibility criteria: eligible ages (years): 18.0-75.0,  Muscular Dystrophy, Oculopharyngeal Man or woman <18-75> years old Oculopharyngeal muscular dystrophy confirmed by genetic diagnosis (mutation of the GCG) on the chromosome 14) Oculopharyngeal muscular dystrophy with UES dysfunction salivary or alimentary stasis at fibroscopy of swallowing above the UES decreased opening of the UES at videofluoroscopy of swallowing A decreased of the pharyngeal propulsion may be associated Written consent of the patient  History of myotomy of the UES in the context of the Oculopharyngeal muscular Dystrophy HIV, hepatitis B or C tuberculosis) Lupus, rheumatoid polyarthritis, sarcoïdosis, collagenosis)  Other neuromuscular diseases  History of malignant tumor  History of neck radiotherapy  Renal failure (creatinine clearance <60ml/min) Liver failure  Pregnancy
Patient description: A 52-year-old African American man with a history of heavy smoking and drinking, describes progressive dysphagia that began several months ago. He first noticed difficulty swallowing meat. His trouble swallowing then progressed to include other solid foods, soft foods, and then liquids. He is able to locate the point where food is obstructed at the lower end of his sternum. He has lost a total of 25 pounds.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  First Line Chemotherapy Capecitabine Plus Cisplatin Versus Capecitabine Plus Paclitaxel Advanced or Recurrent Esophageal Squamous Cell Carcinoma Histologically confirmed metastatic, or recurrent esophageal squamous cell carcinoma Age > 18 years ECOG performance status 0 At least one measurable lesion(s) by Life expectancy ≥ 3 months Patients may have received prior adjuvant chemotherapy with 5-FU with cisplatin as long as it has been 12 months since completion of regimen No previous palliative chemotherapy Prior radiotherapy must be completed 4 weeks before study entry Adequate bone marrow function (≥ ANC 1,500/ul, ≥ platelet 100,000/ul, ≥ Hemoglobin 9.0 g/dl) Adequate renal function (≤ serum creatinine 1.5 mg/dl or CCr ≥ 50 ml/min)  Other tumor types such as adenocarcinoma, small cell carcinoma Evidence of CNS metastasis Contraindication to any drug contained in the chemotherapy regimen Previous adjuvant treatment with 5-FU, cisplatin, capecitabine or paclitaxel finished less than 1 year Evidence of serious gastrointestinal bleeding History of another malignancy within the last five years except cured basal cell carcinoma of skin and cured carcinoma in-situ of uterine cervix Clinically significant cardiac disease (e.g. severe non-compensated hypertension, non-compensated heart failure, dilated cardiomyopathy, and coronary heart disease with ST segment depression in ECG) or myocardial infarction within the last 6 months Serious pulmonary conditions/illness (e.g. chronic lung disease with hypoxemia) Serious metabolic disease such as severe non-compensated diabetes mellitus History of significant neurologic or psychiatric disorders
Patient description: A 52-year-old African American man with a history of heavy smoking and drinking, describes progressive dysphagia that began several months ago. He first noticed difficulty swallowing meat. His trouble swallowing then progressed to include other solid foods, soft foods, and then liquids. He is able to locate the point where food is obstructed at the lower end of his sternum. He has lost a total of 25 pounds.

Clinical trial eligibility criteria: eligible ages (years): 20.0-80.0,  Esophageal Cancer Histologically confirmed primary cancer of esophagus Must be dysphagia caused by esophageal cancer Without esophageal fistulas Must be an inpatient Life expectancy is over 6 months  Esophageal fistulas Tracheal compression with symptoms WBC <2000/mm3 and Platelet count <50,000/mm3 Concurrent therapies after stenting:surgery, chemotherapy,radiotherapy, Traditional Chinese Medicine
Patient description: A 52-year-old African American man with a history of heavy smoking and drinking, describes progressive dysphagia that began several months ago. He first noticed difficulty swallowing meat. His trouble swallowing then progressed to include other solid foods, soft foods, and then liquids. He is able to locate the point where food is obstructed at the lower end of his sternum. He has lost a total of 25 pounds.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Resectable Esophageal Cancer Histologically proven resectable adenocarcinoma of the lower oesophagus and gastric-oesophageal junction Tumour stage: T2-3 N0-1 M0, as assessed by endoscopic ultrasound and CT-scan of thorax and abdomen and ultrasound neck region. For the patients treated in this study the gastro-oesophageal junctional tumors will be staged as oesophageal tumors with respect to their lymphnode metastases Age >18y and written informed consent after at least 4 days of deliberation time from the moment the patient information has been given and has been explained Weight loss < 10% in 0.5 yr WHO performance status 0-1 No prior radiotherapy or chemotherapy for the adenocarcinoma of the oesophagus  Previous malignancy other than basal cell carcinoma of the skin or local resection for cervical carcinoma in situ Inadequate organ function as defined by Inadequate haematology (Hb < 5,5 mmol/L (red blood cell transfusions are allowed to increase the Hb at the discretion of the investigator) neutrophils < 1,5 109/L -platelets <100*109/L) Liver enzyme elevation (bili > 1,5*ULN ASAT > 2,5*ULN ALAT > 2,5*ULN) or Impaired renal function (creatinine clearance by cockcroft < 60 cc/min) Proteinuria >1,0gr/24hr Tumour stage: M1a and/or tumour length > 8 cm and/or > 5 cm radially
Patient description: A 52-year-old African American man with a history of heavy smoking and drinking, describes progressive dysphagia that began several months ago. He first noticed difficulty swallowing meat. His trouble swallowing then progressed to include other solid foods, soft foods, and then liquids. He is able to locate the point where food is obstructed at the lower end of his sternum. He has lost a total of 25 pounds.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Esophageal Cancer Histologically proven adenocarcinoma, squamous cell carcinoma, or adenosquamous carcinoma of the esophagus Locally advanced disease (any T, N0 or N1, M0 or M1a) No metastatic disease, except for tumor involvement of the upper third of the esophagus or cervical esophageal tumor with regional nodes, or tumor involvement of the lower third of the esophagus with celiac nodes (M1a) Cervical primary tumor with positive supraclavicular or cervical lymph nodes (defined as N1) allowed No radiographic evidence of enlarged (≥ 1.5 cm) celiac lymph nodes by CT scan or echography No small cell or undifferentiated carcinoma of the esophagus No multiple carcinomas of the esophagus (i.e., > 1 esophageal tumor) No cardia tumor (Siewert II) or gastric tumor extension to the esophagus (Siewert III) Esophageal tumor extension to the cardia (Siewert I) (center of the tumor lying > 1 cm-5 cm above gastroesophageal junction) allowed Inoperable disease OR surgery is contraindicated
Patient description: A 52-year-old African American man with a history of heavy smoking and drinking, describes progressive dysphagia that began several months ago. He first noticed difficulty swallowing meat. His trouble swallowing then progressed to include other solid foods, soft foods, and then liquids. He is able to locate the point where food is obstructed at the lower end of his sternum. He has lost a total of 25 pounds.

Clinical trial eligibility criteria: eligible ages (years): 18.0-65.0,  Tobacco Dependence Alcohol Dependence Heavy Smokers/Heavy Drinkers Treatment seeking smokers Age 18 to 65 years Smoke ≥ 10 cigarettes per day Fagerstrom Test of Nicotine Dependence score > 3 Alcohol Use Disorders Identification Test (AUDIT) > 8 Drink > 25 drinks per week for males or > 20 drinks per week for females Able to provide written informed consent (Heavy Smokers/Social Drinkers) Treatment seeking smokers  (Heavy Smokers/Heavy Drinkers) Any medical condition requiring immediate investigation or treatment Beck Depression Inventory score >16 Insulin-dependent diabetes Drink > 70 standard alcoholic drinks per week for males or drink > 52 standard alcoholic drinks per week for females Pregnancy or lactation Current DSM-IV Axis 1 psychiatric disorder Regular use of any therapeutic or recreational psychoactive drug use during the last three months or other substance use disorder, with the exception of tobacco and alcohol (Heavy Smokers/Social Drinkers) Any medical condition requiring immediate investigation or treatment
Patient description: A 52-year-old African American man with a history of heavy smoking and drinking, describes progressive dysphagia that began several months ago. He first noticed difficulty swallowing meat. His trouble swallowing then progressed to include other solid foods, soft foods, and then liquids. He is able to locate the point where food is obstructed at the lower end of his sternum. He has lost a total of 25 pounds.

Clinical trial eligibility criteria: eligible ages (years): 18.0-75.0,  Suspected Eosinophilic Esophagitis Male and female volunteers ≥18 years old Patients with known or suspected Eosinophilic Esophagitis Patients undergoing upper endoscopy for recent food impaction or complaint of dysphagia  Use of oral corticosteroids Significant medical conditions that in the investigator's judgment would compromise the subject's health and safety Contraindication to esophageal dilation based on investigator's judgment Esophageal motility abnormalities not thought to be related to Eosinophilic Esophagitis
Patient description: A 52-year-old African American man with a history of heavy smoking and drinking, describes progressive dysphagia that began several months ago. He first noticed difficulty swallowing meat. His trouble swallowing then progressed to include other solid foods, soft foods, and then liquids. He is able to locate the point where food is obstructed at the lower end of his sternum. He has lost a total of 25 pounds.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Lung Cancer Precancerous Condition Meets 1 of the following Smoker with no disease Smoker with airflow obstruction and abnormal sputum cytology Smoker with lung cancer Smoker with various grades of dysplasia Non-smoker Not specified Not specified
Patient description: A 52-year-old African American man with a history of heavy smoking and drinking, describes progressive dysphagia that began several months ago. He first noticed difficulty swallowing meat. His trouble swallowing then progressed to include other solid foods, soft foods, and then liquids. He is able to locate the point where food is obstructed at the lower end of his sternum. He has lost a total of 25 pounds.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Esophageal Cancer Diagnosis of adenocarcinoma of the esophagus Stage I-IV disease Received cisplatin-based treatment on clinical trial ECOG-1201 Not specified Not specified
Patient description: A 52-year-old African American man with a history of heavy smoking and drinking, describes progressive dysphagia that began several months ago. He first noticed difficulty swallowing meat. His trouble swallowing then progressed to include other solid foods, soft foods, and then liquids. He is able to locate the point where food is obstructed at the lower end of his sternum. He has lost a total of 25 pounds.

Clinical trial eligibility criteria: eligible ages (years): 18.0-54.0,  Haemophilus Influenzae (NTHI) for Inoculated Volunteers Healthy 18-54 years old (male or female) with no chronic medical conditions with the exception of well-controlled hypertension Availability for study visits over the next 1 month Normal hemoglobin, white blood cell count, creatinine, alanine aminotransferase (ALT), platelet count Signed informed consent form In good health as determined by medical history and physical exam on the screening evaluation [including heart rate 55-100 beats per minute (bpm); blood pressure: systolic 90-140 mm Hg and diastolic 50-90 mm Hg]. If the subject is a well trained athlete by the judgment of the Principal Investigator (PI), heart rate of 40-100 bpm is acceptable Negative urine pregnancy test for women of childbearing potential If the subject is female and of childbearing potential, she agrees to use acceptable contraception and not become pregnant for the duration of the study. (Acceptable contraception includes abstinence, implants, injectables, combined oral contraceptives, effective intrauterine devices, or a vasectomized partner) Negative human immunodeficiency virus (HIV) enzyme linked immunosorbent assay (ELISA) for HIV 1 and 2 or indeterminate Western blot or other assay confirming that the serostatus does not reflect HIV infection, negative hepatitis C and hepatitis B serology or other assay confirming that the serostatus does not reflect active hepatitis C virus (HCV) or hepatitis B virus (HBV) infection Negative urine protein and glucose by dipstick  for Inoculated Volunteers Acute illness within the week prior to inoculation Acute febrile illness (oral temperature greater than or equal to 100.4 degrees Fahrenheit) on the day of inoculation Allergic rhinitis requiring therapy in the past year Treatment for sinusitis, otitis, chronic bronchitis, pneumonia, bronchospasm or asthma in the past 5 years Abnormal gag reflex Active drug or alcohol abuse Smoking tobacco within the past year Average ingestion of more than one alcoholic beverage per day for women or two alcoholic beverages per day for men Splenectomy or disease that results in functional asplenism such as sickle cell diseases
Patient description: A 52-year-old African American man with a history of heavy smoking and drinking, describes progressive dysphagia that began several months ago. He first noticed difficulty swallowing meat. His trouble swallowing then progressed to include other solid foods, soft foods, and then liquids. He is able to locate the point where food is obstructed at the lower end of his sternum. He has lost a total of 25 pounds.

Clinical trial eligibility criteria: eligible ages (years): 20.0-70.0,  Tracheal Intubation ASA physical status I-II, aged between 20 and 70 years scheduled for elective laparoscopic cholecystectomy under general anesthesia with endotracheal intubation  recent respiratory tract infection or sore throat who were using analgesics or steroid preoperatively who have risk factors for oral cavity infection the surgical duration < 60 minutes or > 300 minutes
Patient description: A 52-year-old African American man with a history of heavy smoking and drinking, describes progressive dysphagia that began several months ago. He first noticed difficulty swallowing meat. His trouble swallowing then progressed to include other solid foods, soft foods, and then liquids. He is able to locate the point where food is obstructed at the lower end of his sternum. He has lost a total of 25 pounds.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  HIV Infections Tobacco Dependence HIV-infected patients adults regular smokers (at least 10 cigarettes a day during the last year) motivated to stop smoking followed in one of the participating clinical ward signed written inform consent  current co-dependency to another psychoactive substance ongoing depressive episode history of suicidal attempt ongoing treatment by interferon treatment by efavirenz for less than three months or not tolerated previous use of varenicline ongoing treatment by bupropion-SR or nicotinic substitute ongoing pregnancy ongoing breastfeeding hypersensitivity to varenicline or to one of its excipients
Patient description: A 52-year-old African American man with a history of heavy smoking and drinking, describes progressive dysphagia that began several months ago. He first noticed difficulty swallowing meat. His trouble swallowing then progressed to include other solid foods, soft foods, and then liquids. He is able to locate the point where food is obstructed at the lower end of his sternum. He has lost a total of 25 pounds.

Clinical trial eligibility criteria: eligible ages (years): 18.0-50.0,  Healthy Age 18-50 years, inclusive Expressed interest and ability to fulfill the study requirements Be in general good health as determined by a screening evaluation within 30 days of the first dose of LGG or placebo Able to ingest the study drug (LGG or placebo) dissolved in a small amount of cow's milk or soy milk orally (no feeding tube) Willing to prevent pregnancy Women must agree not to become pregnant or breastfeed from the time of study enrollment until at least 3 months after the last dose of study drug. If a woman is sexually active and has no history of hysterectomy or tubal ligation, she must agree to practice an acceptable method of birth control, such as hormonal or barrier birth control. A woman is eligible if she is monogamous with a vasectomized male. Sexually active male volunteers without vasectomy must agree to use a barrier method of contraception for 3 months after the last dose of study drug Willing to comply with protocol and report on compliance and side effects during study period Informed consent obtained and signed prior to screening  Consumption of supplements or food products containing LGG or probiotics 30 days prior to the start of the study or consumption of yogurt that has "live and active cultures" seal Known or suspected allergies to probiotics, Lactobacillus, microcrystalline cellulose, gelatin, or any antibiotic that may be used to treat LGG bacteremia or infection (Ampicillin, Clindamycin, Moxifloxacin) Received oral or parenteral antibiotics within 4 weeks of enrollment or prescribed antibiotics on day of enrollment Drug or alcohol abuse within previous 12 months Major surgery or endoscopy within last 3 months Daily prescription or over-the-counter medicines except for vitamins, birth control products, and hormone replacement therapy Presence of any of the following Abnormal vital signs or clinically significant physical findings such as murmur (other than functional), hepatosplenomegaly, jaundice, lymphadenopathy, or focal neurological deficit Indwelling catheter or implanted hardware/prosthetic device or feeding tube Febrile illness (oral temperature >37 degrees Celsius) or one or more episodes of diarrhea within 72 hours of baseline visit (first dose of study drug)
Patient description: A 52-year-old African American man with a history of heavy smoking and drinking, describes progressive dysphagia that began several months ago. He first noticed difficulty swallowing meat. His trouble swallowing then progressed to include other solid foods, soft foods, and then liquids. He is able to locate the point where food is obstructed at the lower end of his sternum. He has lost a total of 25 pounds.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Non-Small Cell Lung Cancer Patients diagnosed with advanced NSCLC stage IIIB/IV who have not received previous chemotherapy Radiotherapy or both and who have tumor tissue embedded in paraffin blocks or formalin-fixed These patients must sign an informed consent letter  Patients who refuse to participate in the study or those who decide to withdraw from it Patients without tumor tissue or with a poor quality sample
Patient description: A 52-year-old African American man with a history of heavy smoking and drinking, describes progressive dysphagia that began several months ago. He first noticed difficulty swallowing meat. His trouble swallowing then progressed to include other solid foods, soft foods, and then liquids. He is able to locate the point where food is obstructed at the lower end of his sternum. He has lost a total of 25 pounds.

Clinical trial eligibility criteria: eligible ages (years): 18.0-64.0,  Sore Throat Pain Female patients undergoing outpatient laparoscopic gynecologic surgery ASA PS I and II Age between 18 and 64 years Fluent in English  History of recent respiratory tract infection Pregnancy, breastfeeding Current treatment with analgesics Current use of corticosteroids Anticipated difficult intubation Risk factors for post-operative aspiration